Dynavax Technologies
Berkeley · Founded 1996
About Dynavax Technologies
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Company Facts
- Founded: 1996
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $1.6B
- Funding stage: M&A
- Last round: Post-IPO Debt (Mar 2025)
- Ticker: nasdaq:DVAX
- Website: dynavax.com
- Phone: +1 510 848 1327
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/dynavax-technologies-15250 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.